证券代码：688613 证券简称：奥精医疗 公告编号：2025-024 奥精医疗科技股份有限公司 2024年年度股东大会决议公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 本次会议是否有被否决议案：无 一、 会议召开和出席情况 （一） 股东大会召开的时间：2025 年 5 月 16 日 （二） 股东大会召开的地点：北京市大兴区生物医药产业基地庆丰西路 69 号 35 号楼 3 层 （三） 出席会议的普通股股东、特别表决权股东、恢复表决权的优先股股东及 其持有表决权数量的情况： | 1、出席会议的股东和代理人人数 | 41 | | --- | --- | | 普通股股东人数 | 41 | | 2、出席会议的股东所持有的表决权数量 | 36,662,578 | | 普通股股东所持有表决权数量 | 36,662,578 | | 3、出席会议的股东所持有表决权数量占公司表决权数量的比 | 26.7593 | | 例（%） | | | 普通股股东所持有表决权数量占公司表决权数量的比例（%） | 26.7593 | ...

北京市中伦律师事务所 关于奥精医疗科技股份有限公司 2024 年年度股东大会的 法律意见书 致：奥精医疗科技股份有限公司 北京市中伦律师事务所（以下简称"本所"）接受奥精医疗科技股份有限公 司（以下简称"公司"）委托，指派律师见证公司 2024 年年度股东大会（以下 简称"本次股东大会"）。本所律师根据《中华人民共和国公司法》（以下简称 "《公司法》"）、《中华人民共和国证券法》（以下简称"《证券法》"）、 《上市公司股东会规则》（以下简称"《股东会规则》"）、《律师事务所从事 证券法律业务管理办法》等相关法律、法规、规章、规范性文件及《奥精医疗科 技股份有限公司章程》（以下简称"《公司章程》"）的规定，对本次股东大会 的相关事项进行见证并出具法律意见。 为出具本法律意见书，本所律师审查了公司本次股东大会的有关文件和材料。 本所律师出具本法律意见书基于公司向本所律师提供的一切原始材料、副本、复 印件等材料、口头证言均是真实、准确、完整和有效的，不存在隐瞒记载、虚假 陈述或重大遗漏，有关文件的印章和签字均真实、有效，有关副本、复印件等材 料均与原始材料一致。 1 法律意见书 在本法律意见书中，本所律师仅对本次股 ...

华泰联合证券有限责任公司 关于奥精医疗科技股份有限公司 2024 年度持续督导跟踪报告 根据《证券法》《证券发行上市保荐业务管理办法》《上海证券交易所科创板 股票上市规则》等有关法律、法规的规定，华泰联合证券有限责任公司（以下简称 "华泰联合证券"或"保荐机构"）作为奥精医疗科技股份有限公司（以下简称 "奥精医疗"、"公司"或"发行人"）首次公开发行股票的保荐机构，对奥精医 疗进行持续督导，并出具 2024 年度（以下简称"本报告期"或"报告期"）持续 督导跟踪报告。 一、保荐机构和保荐代表人发现的问题及整改情况 此外，近年来，国家为鼓励医疗器械加快技术创新、加速进口替代，在政策层 面给予了较大的扶持力度。如果未来行业鼓励政策发生变化，则可能对公司的经营 发展造成一定影响。此外，随着中国医疗卫生体制改革的不断深入和社会医疗保障 体制的逐步完善，行业相关监管政策将不断完善、调整，中国医疗卫生市场的政策 环境可能面临重大变化。如公司不能及时调整经营策略以适应医疗卫生体制改革带 来的市场规则和监管政策的变化，将对公司的经营发展造成不利影响。 （二）核心竞争力风险 我国对医疗器械实行分类注册制度。公司的矿化胶原人工骨 ...

首次公开发行股票并在科创板上市 之保荐总结报告书 保荐机构名称 华泰联合证券有限责任公司 保荐机构编号 Z26774000 一、保荐机构及保荐代表人承诺 1、保荐总结报告书和证明文件及其相关资料的内容不存在虚假记载、误导 性陈述或重大遗漏，保荐机构及保荐代表人对其真实性、准确性、完整性承担法 律责任。 2、本机构及本人自愿接受中国证券监督管理委员会（以下简称"中国证监 会"）、上海证券交易所对保荐总结报告书相关事项进行的任何质询和调查。 华泰联合证券有限责任公司 关于奥精医疗科技股份有限公司 3、本机构及本人自愿接受中国证监会按照《证券发行上市保荐业务管理办 法》的有关规定采取的监管措施。 二、保荐机构基本情况 | 情况 | 内容 | | --- | --- | | 保荐机构名称 | 华泰联合证券有限责任公司 | | 注册地址 | 深圳市前海深港合作区南山街道桂湾五路 128 号前海深港基金小 | | | 镇 B7 栋 401 | | 主要办公地址 | 北京市西城区丰盛胡同 22 号丰铭国际大厦 A 座 6 层 | | 法定代表人 | 江禹 | | 联系人 | 徐妍薇 | | 联系电话 | 010-56839 ...

Company Overview - Aojing Medical Technology Co., Ltd. focuses on the research, development, production, and sales of high-end biomedical materials and related medical devices, recognized as a national high-tech enterprise [1] - The company has consistently aimed to meet clinical needs through continuous innovation in products and technology, primarily researching and developing mineralized collagen artificial bone repair materials [1] Financial Performance - As of the first quarter of 2025, Aojing Medical reported revenue of 42.46 million yuan, a year-on-year decrease of 10.35% [1] - The net profit for the same period was 1.04 million yuan, reflecting a significant year-on-year decline of 84.99% [1] - The gross profit margin stood at 60.71% [1] Market Position - Aojing Medical's latest closing price was 16.15 yuan, with a market capitalization of 2.213 billion yuan and a price-to-book ratio of 1.57 [1] - The company is among eight institutions holding shares, with a total of 35.38 million shares valued at 561 million yuan [1] Industry Comparison - Aojing Medical's price-to-earnings (P/E) ratio (TTM) is -119.23, significantly lower than the industry average of 49.02 [2] - The industry median P/E ratio is 36.25, indicating that Aojing Medical is underperforming compared to its peers [2]

证券代码：688613 证券简称：奥精医疗 奥精医疗科技股份有限公司 2024 年年度股东大会 会议资料 二〇二五年五月 奥精医疗科技股份有限公司（688613） 股东大会会议资料 目 录 | 年年度股东大会会议须知 | | 3 | 2024 | | --- | --- | --- | --- | | 年年度股东大会会议议程 | | 5 | 2024 | | 年年度股东大会会议议案 | | 7 | 2024 | | 议案一：关于公司 | 2024 | 年度董事会工作报告的议案 7 | | | 议案二：关于公司 | 2024 | 年度监事会工作报告的议案 12 | | | 议案三：关于公司 | 2024 | 年度财务决算报告的议案 16 | | | 议案四：关于公司续聘立信会计师事务所（特殊普通合伙）为公司 | | 2025 年度财 | | | 务审计机构的议案 | | 24 | | | 议案五：关于公司 | 2024 | 年年度报告及其摘要的议案 25 | | | 议案六：关于公司 | 2025 | 年度董事、监事及高级管理人员薪酬方案的议案 .. 26 | | | 议案七：关于为公司董监高人员购买责任险的议 ...

Investment Rating - The investment rating for the company is "Buy" [1] Core Views - The company's performance is under short-term pressure due to centralized procurement, but market expansion is accelerating, indicating strong growth momentum. In 2024, the company achieved revenue of 206 million yuan, a year-on-year decrease of 9.03%, and a net profit loss of 13 million yuan, a year-on-year decline of 123.35%. The company is actively expanding its domestic market and has made breakthroughs in international markets [2][4] - The "Bone Gold" product line is expected to see increased sales volume, while the company is also positioning itself in the implant business to create new growth points. The revenue from the "Bone Gold" product was 145 million yuan, with a gross margin of 72.84%. The company has also acquired HumanTechDental in Germany to expand its dental implant business [2][4] - Revenue forecasts for 2025-2027 are projected at 270 million, 355 million, and 470 million yuan, with year-on-year growth rates of 31.0%, 31.5%, and 32.3%, respectively. The net profit for the same period is expected to be 42 million, 66 million, and 98 million yuan, with significant growth rates [2][4] Summary by Sections Financial Performance - In 2024, the company reported total revenue of 206 million yuan, a decrease of 9.03% year-on-year, and a net profit loss of 13 million yuan, a decline of 123.35% year-on-year. The first quarter of 2025 saw revenue of 42 million yuan, down 10.35% year-on-year, with a net profit of 0.01 yuan, a decrease of 84.99% year-on-year [2][4] - The company is expected to recover with projected revenues of 270 million, 355 million, and 470 million yuan for 2025, 2026, and 2027, respectively, with corresponding net profits of 42 million, 66 million, and 98 million yuan [4] Market Expansion - The company has developed over 900 new hospitals in 2024, a 90% increase year-on-year, primarily due to the implementation of centralized procurement. This expansion is expected to lay a solid foundation for domestic revenue growth [2] - The company has made significant strides in international markets, completing clinical trials for its artificial bone repair products in Southeast Asia and Latin America [2] Product Lines - The "Bone Gold" product line generated revenue of 145 million yuan, with a gross margin of 72.84%. The decline in gross margin is attributed to lower factory prices following centralized procurement [2] - The "Tooth Bay" dental repair material performed well, achieving revenue of 39 million yuan, an increase of 82.1% year-on-year. The acquisition of HumanTechDental is expected to enhance the synergy between the dental implant and "Tooth Bay" businesses [2]

证券代码：688613 证券简称：奥精医疗 公告编号：2025-023 奥精医疗科技股份有限公司 2023 年限制性股票激励计划首次授予部分 第二个归属期归属结果暨股份上市公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 本次股票上市类型为股权激励股份；股票认购方式为网下，上 市股数为1,457,000股。 本次股票上市流通总数为1,457,000股。 本次股票上市流通日期为2025 年 5 月 8 日。 根据中国证券监督管理委员会、上海证券交易所、中国证券登记结算有限责 任 公司上海分公司相关业务规定，奥精医疗科技股份公司（以下简称"公司"） 于近日收到中国证券登记结算有限责任公司上海分公司出具的《证券变更登记证 明》，公司完成了 2023 年限制性股票激励计划首次授予部分第二个归属期的股份 登记工作。现将有关情况公告如下： 一、本次限制性股票归属的决策程序及相关信息披露 1、2023 年 3 月 23 日，公司召开第二届董事会第二次会议，审议通过了《关 于审议公司<2023 年限制性股票激励计划（草 ...

正式报名：首届全球心血管大会 | 赠送纸质白皮书 合作伙伴征集：2025全球手术机器人大会 2025年4月26日， 奥精医疗 发布了2024年年报以及2025年一季报。 | 主要会计数据 | 2024年 | 2023年 | 本期比上年同 | 2022年 | | --- | --- | --- | --- | --- | | | | | 期增减(%) | | | 营业收入 | 206,033,014.77 | 226,475,894.98 | -9.03 | 245,305,139.72 | | 扣除与主营业务无关的业务收 入和不具备商业实质的收入后 | 200,430,853.46 | 218,427,930.77 | -8.24 | 240,282,309.74 | | 的营业收入 | | | | | | 归属于上市公司股东的净利润 | -12,662,162.69 | 54,231,840.71 | -123.35 | 95,217,271.83 | | 归属于上市公司股东的扣除非 经常性损益的净利润 | -28,371,119.81 | 25,766,199.74 | -210.11 | 80,059, ...

Group 1 - The U.S. "reciprocal tariffs" are putting significant pressure on the global economy and trade system, particularly affecting industries like semiconductors, automobiles, and pharmaceuticals [1] - Aojing Medical (688613.SH) stated that its overseas business is primarily focused on emerging markets in Southeast Asia, and the U.S. tariff policy will not impact its operations [1] - The company emphasizes its long-term global strategy, aiming to enhance product competitiveness through continuous technological innovation and to expand into high-growth emerging markets [1] Group 2 - The bone repair materials industry is experiencing a trend of domestic substitution, with artificial bone materials gradually replacing natural bone due to their advantages [2] - Aojing Medical's mineralized collagen artificial bone repair materials have achieved international advanced levels in key indicators, addressing limitations of natural bone materials [2] - The market share of artificial bone has rapidly increased from less than 30% in 2018 to a dominant position, indicating a clear trend towards accelerated substitution [2] Group 3 - The domestic bone repair materials industry has seen rapid development, with domestic brands catching up to or surpassing imported brands in technology [3] - National centralized procurement policies are driving domestic substitution, further squeezing the market space for imported products [3] - Aojing Medical's mineralized collagen artificial bone repair materials have become a benchmark for high-end orthopedic products in China, with significant growth in hospital adoption following successful procurement [3] Group 4 - Aojing Medical's product line includes various artificial bone repair materials, which are expected to enhance market share due to their inclusion in national procurement [4] - The company is diversifying its product offerings to mitigate the impact of price reductions from centralized procurement [4] - Aojing Medical is expanding into the dental implant market through the acquisition of HumanTech Dental, which is expected to create a second growth curve for the company [5] Group 5 - The company is focusing on emerging markets in Southeast Asia, having obtained regulatory approvals in Malaysia, Indonesia, and Vietnam, which are expected to drive growth [5][6] - The Southeast Asian orthopedic repair materials market is projected to grow at a compound annual growth rate of 21.4% from 2023 to 2028, significantly outpacing the global average [5] - Aojing Medical's early entry into the Southeast Asian market provides a competitive advantage amid the U.S.-China trade tensions [5] Group 6 - Aojing Medical's supply chain strategy emphasizes resilience and efficiency, aiming to combine low costs with rapid response capabilities [6] - The core materials for the company's artificial bone products are I-type collagen and hydroxyapatite, with plans for self-sufficiency in raw materials to reduce production costs [6] - A new production line set to launch in November 2024 will significantly increase the company's annual production capacity, supporting both domestic and international demand [6] Group 7 - Aojing Medical is leveraging technological innovation and a diversified product strategy to build a sustainable growth model in a competitive environment [7] - The company's strategic planning and rapid progress position it well to capitalize on growth opportunities in the bone repair materials market [7]